Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Japan's First DPP-4 Inhibitor Sitagliptin to Be Approved
October 12, 2009
- Gov't to Procure Flu Vaccines for 77 Million Persons
October 12, 2009
- Eisai Applies for Non-Erosive GERD in Japan as Additional Indication for Pariet
October 12, 2009
- SURVEY／20% of Respondents Reluctant to Receive New-Type Flu Vaccines
October 12, 2009
- Eisai, Abbott Japan Apply for Humira for Crohn's Disease
October 12, 2009
- SEMINAR／Patients' Awareness of RA Treatment Insufficient: Prof. Yamamoto
October 12, 2009
- Parliamentary Secretary Shinya Adachi to Evaluate Chuikyo Membership
October 12, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 12, 2009
- REGULATORY NEWS IN BRIEF
October 12, 2009
- Mediceo to Further Cut Distribution Costs
October 12, 2009
- Astellas Concentrates Drug Discovery Functions in Tsukuba
October 12, 2009
- Eisai Ties Up with DNDi for Chagas Disease
October 12, 2009
- New Antibody Drugs for Cancer Highlighted at JCA Annual Meeting
October 12, 2009
- Korosho to Support Development of 12 Unapproved Drugs
October 12, 2009
- MEDICAL DEVICE NEWS IN BRIEF
October 12, 2009
- R&D NEWS IN BRIEF
October 12, 2009
- NEW PRODUCTS
October 12, 2009
- Switch OTC Drugs Are Major Business Driver: SSP
October 12, 2009
- Ajinomoto Pharm. Aims at Sales of ¥100 Bil. in 5 Years
October 12, 2009
- Dr Hayakawa Calls For Flexible Applications of Guidance on Biosimilars
October 12, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…